Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Life Sci. 2021 Apr 1;270:119118. doi: 10.1016/j.lfs.2021.119118. Epub 2021 Feb 3.
Pancreatic cancer is among the most lethal malignancies with poor prognosis and patients become chemoresistant to current therapies, supporting further investigations to identify new therapeutic regimens in the treatment of this condition. Preclinical and clinical studies now appear to support the role of the renin-angiotensin system (RAS) in the regulation of tumor growth, angiogenesis, and metastasis in different malignancies including pancreatic cancer. These studies suggest that RAS blockers; Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs); could have anti-carcinogenic effects and improve clinical outcomes in the management of pancreatic cancer. Here we provided an overview of ACE inhibitors and ARBs as a potential therapeutic option in the treatment of pancreatic cancer.
胰腺癌是预后最差的恶性肿瘤之一，患者对现有治疗药物产生耐药性，因此需要进一步研究以确定治疗这种疾病的新疗法。临床前和临床研究似乎支持肾素-血管紧张素系统（RAS）在不同恶性肿瘤（包括胰腺癌）的肿瘤生长、血管生成和转移中的调节作用。这些研究表明，RAS 阻滞剂；血管紧张素转换酶（ACE）抑制剂和血管紧张素受体阻滞剂（ARB）；可能具有抗癌作用，并改善胰腺癌管理中的临床结局。在这里，我们概述了 ACE 抑制剂和 ARB 作为治疗胰腺癌的一种潜在治疗选择。
